Hartmut Kristeleit

  • Citations Per Year
Learn More
Afatinib is an irreversible ErbB family blocker currently under evaluation in late-stage clinical trials. This study primarily assessed the cardiac safety, pharmacokinetics and antitumor activity of afatinib in cancer patients. In this multicenter, Phase II, open-label, single-arm trial, 60 patients with solid tumors who were expected to express epidermal(More)
2613^ Background: Afatinib (BIBW 2992) is an oral, irreversible ErbB family blocker. This trial prospectively evaluated the possible proarrhythmic potential of afatinib by assessing QTc interval, as well as its PK and clinical efficacy. METHODS Patients (pts) with tumors known to overexpress EGFR or HER2, including those with brain metastases and GBM were(More)
The addition of adjuvant trastuzumab therapy for 1 year to standard chemotherapy significantly improved disease-free survival and overall survival versus chemotherapy alone in a number of pivotal early breast cancer studies. Here we review long-term follow-up data on the efficacy, cardiac safety, and general safety of trastuzumab in these pivotal studies.(More)
The molecular success story in non-small-cell lung cancer (NSCLC) has not been fast developing. Despite the discovery of an oncogenic KRAS mutation in NSCLC in 1984 [1], it was not until 2004 that epidermal growth factor receptor (EGFR) mutations were found to predict response to gefitinib [2] and erlotinib [3]. Since then, lung cancer has evolved from a(More)
Igeneon, under license from Protein Design Labs, is developing IGN-311, an intravenous humanized monoclonal antibody against the Lewis Y carbohydrate antigen, as a potential agent for the passive immunotherapy of cancer, particularly epithelial tumors affecting breast, colon, gastric and pancreatic tissues. A phase I/II trial of IGN-311 was initiated in(More)
  • 1